These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22879929)

  • 1. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.
    Hanson KE; Pfeiffer CD; Lease ED; Balch AH; Zaas AK; Perfect JR; Alexander BD
    PLoS One; 2012; 7(8):e42282. PubMed ID: 22879929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis.
    Pang YK; Ip M; You JHS
    Eur J Clin Microbiol Infect Dis; 2017 Jan; 36(1):187-194. PubMed ID: 27686799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L; Shoham S; Vazquez J; Reboli A; Betts R; Barron MA; Schuster M; Judson MA; Revankar SG; Caeiro JP; Mangino JE; Mushatt D; Bedimo R; Freifeld A; Nguyen MH; Kauffman CA; Dismukes WE; Westfall AO; Deerman JB; Wood C; Sobel JD; Pappas PG
    Clin Infect Dis; 2014 May; 58(9):1219-26. PubMed ID: 24550378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial.
    Bloos F; Held J; Schlattmann P; Brillinger N; Kurzai O; Cornely OA; Thomas-Rüddel D
    Trials; 2018 Sep; 19(1):472. PubMed ID: 30180873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
    Liew YX; Teo J; Too IA; Ngan CC; Tan AL; Chlebicki MP; Kwa AL; Lee W
    BMC Infect Dis; 2015 Jul; 15():256. PubMed ID: 26137997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum 1,3-beta-d-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery.
    Prattes J; Hoenigl M; Rabensteiner J; Raggam RB; Prueller F; Zollner-Schwetz I; Valentin T; Hönigl K; Fruhwald S; Krause R
    Mycoses; 2014 Nov; 57(11):679-86. PubMed ID: 25040144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.
    Martínez-Jiménez MC; Muñoz P; Valerio M; Vena A; Guinea J; Bouza E
    J Antimicrob Chemother; 2015 Nov; 70(11):3107-15. PubMed ID: 26311840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis.
    Kritikos A; Poissy J; Croxatto A; Bochud PY; Pagani JL; Lamoth F
    J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32238435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
    Cento V; Alteri C; Mancini V; Gatti M; Lepera V; Mazza E; Moioli MC; Merli M; Colombo J; Orcese CA; Bielli A; Torri S; Gasparini LE; Vismara C; De Gasperi A; Brioschi P; Puoti M; Cairoli R; Lombardi G; Perno CF
    Mycoses; 2020 Dec; 63(12):1299-1310. PubMed ID: 32810888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.
    Posteraro B; Tumbarello M; De Pascale G; Liberto E; Vallecoccia MS; De Carolis E; Di Gravio V; Trecarichi EM; Sanguinetti M; Antonelli M
    J Antimicrob Chemother; 2016 Aug; 71(8):2262-9. PubMed ID: 27125554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan.
    Nucci M; Nouér SA; Esteves P; Guimarães T; Breda G; de Miranda BG; Queiroz-Telles F; Colombo AL
    J Antimicrob Chemother; 2016 Sep; 71(9):2628-33. PubMed ID: 27287231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study.
    Christner M; Abdennadher B; Wichmann D; Kluge S; Pepić A; Aepfelbacher M; Rohde H; Olearo F
    Infection; 2024 Feb; 52(1):73-81. PubMed ID: 37322388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.
    Knitsch W; Vincent JL; Utzolino S; François B; Dinya T; Dimopoulos G; Özgüneş İ; Valía JC; Eggimann P; León C; Montravers P; Phillips S; Tweddle L; Karas A; Brown M; Cornely OA
    Clin Infect Dis; 2015 Dec; 61(11):1671-8. PubMed ID: 26270686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Presence of (1→3)-β-D-Glucan as Prognostic Marker in Patients After Major Abdominal Surgery.
    White PL; Posso R; Parr C; Price JS; Finkelman M; Barnes RA
    Clin Infect Dis; 2021 Oct; 73(7):e1415-e1422. PubMed ID: 32914187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis.
    Jaijakul S; Vazquez JA; Swanson RN; Ostrosky-Zeichner L
    Clin Infect Dis; 2012 Aug; 55(4):521-6. PubMed ID: 22573851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of ß-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients.
    Guitard J; Isnard F; Tabone MD; Antignac M; Brissot E; Senghor Y; Petit A; Leverger G; Hennequin C
    J Infect; 2018 May; 76(5):483-488. PubMed ID: 29432826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study.
    Muñoz P; Vena A; Machado M; Gioia F; Martínez-Jiménez MC; Gómez E; Origüen J; Orellana MÁ; López-Medrano F; Fernández-Ruiz M; Merino P; González-Romo F; Frías I; Pérez-Granda MJ; Aguado JM; Fortún J; Bouza E;
    J Antimicrob Chemother; 2018 Mar; 73(suppl_4):iv6-iv12. PubMed ID: 29608751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of (1,3)-β-D-glucan alone or combined with traditional inflammatory markers in neonatal invasive candidiasis.
    Guo J; Wu Y; Lai W; Lu W; Mu X
    BMC Infect Dis; 2019 Aug; 19(1):716. PubMed ID: 31412796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.